Veracyte, Inc. (VCYT) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
30.65
↓-42% vs avg
5yr avg: 52.76
30Y Low32.1·High73.4
P/FCF
↓
25.68
↓-42% vs avg
5yr avg: 44.54
30Y Low26.8·High58.3
P/B Ratio
↑
2.51
+11% vs avg
5yr avg: 2.25
30Y Low1.1·High6.2
ROE
↑
5.3%
↓+308% vs avg
5yr avg: -2.6%
30Y Low-278%·High5%
Debt/EBITDA
↓
0.41
↓-51% vs avg
5yr avg: 0.85
30Y Low0.4·High1.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
VCYT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Veracyte, Inc. trades at 49.7x earnings, 44% below its 5-year average of 89.5x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a premium of 123%. On a free-cash-flow basis, the stock trades at 25.7x P/FCF, 42% below the 5-year average of 44.5x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.3B | $3.4B | $3.1B | $2.0B | $1.7B | $2.8B | $2.6B | $1.3B | $466M | $222M | $223M |
| Enterprise Value | $2.9B | $3.1B | $2.9B | $1.8B | $1.6B | $2.6B | $2.3B | $1.1B | $413M | $213M | $189M |
| P/E Ratio → | 49.71 | 51.34 | 127.74 | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.29 | 6.56 | 6.94 | 5.54 | 5.73 | 12.74 | 22.18 | 10.70 | 5.06 | 3.08 | 3.43 |
| P/B Ratio | 2.51 | 2.59 | 2.63 | 1.91 | 1.58 | 2.55 | 6.19 | 5.38 | 5.84 | 5.95 | 3.75 |
| P/FCF | 25.68 | 26.79 | 48.51 | 58.33 | — | — | — | — | — | — | — |
| P/OCF | 23.86 | 24.89 | 41.22 | 45.19 | 225.33 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
VCYT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Veracyte, Inc.'s enterprise value stands at 30.7x EBITDA, 42% below its 5-year average of 52.8x. The Healthcare sector median is 14.4x, placing the stock at a 113% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.93 | 6.52 | 4.97 | 5.26 | 12.04 | 19.31 | 9.49 | 4.49 | 2.96 | 2.91 |
| EV / EBITDA | 30.65 | 32.12 | 73.41 | — | — | — | — | — | — | — | — |
| EV / EBIT | 39.51 | 45.00 | 112.91 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 24.24 | 45.56 | 52.38 | — | — | — | — | — | — | — |
VCYT Profitability
Margins and return-on-capital ratios measuring operating efficiency
Veracyte, Inc. earns an operating margin of 14.3%. Operating margins have expanded from -23.8% to 14.3% over the past 3 years, signaling improving operational efficiency. ROE of 5.3% is modest. ROIC of 5.6% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.6% | 69.6% | 66.9% | 68.7% | 65.7% | 66.1% | 64.7% | 69.7% | 64.0% | 60.8% | 60.9% |
| Operating Margin | 14.3% | 14.3% | 3.6% | -23.8% | -13.9% | -37.3% | -30.1% | -12.6% | -24.2% | -36.9% | -44.3% |
| Net Profit Margin | 12.8% | 12.8% | 5.4% | -20.6% | -12.3% | -34.4% | -29.7% | -10.5% | -25.0% | -43.1% | -48.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.3% | 5.3% | 2.2% | -7.0% | -3.4% | -10.0% | -10.6% | -7.9% | -39.3% | -64.1% | -56.6% |
| ROA | 4.9% | 4.9% | 2.0% | -6.6% | -3.1% | -9.2% | -9.5% | -6.4% | -23.1% | -34.5% | -35.6% |
| ROIC | 5.6% | 5.6% | 1.3% | -7.2% | -3.3% | -12.0% | -29.8% | -18.8% | -60.0% | -73.1% | -100.3% |
| ROCE | 5.8% | 5.8% | 1.4% | -8.0% | -3.7% | -10.5% | -10.1% | -8.3% | -25.5% | -34.0% | -38.4% |
VCYT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Veracyte, Inc. carries a Debt/EBITDA ratio of 0.4x, which is very conservative (87% below the sector average of 3.3x). The company holds a net cash position — cash of $363M exceeds total debt of $40M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.04 | 0.01 | 0.01 | 0.02 | 0.03 | 0.06 | 0.32 | 0.68 | 0.43 |
| Debt / EBITDA | 0.41 | 0.41 | 1.28 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.25 | -0.16 | -0.20 | -0.13 | -0.14 | -0.80 | -0.61 | -0.66 | -0.23 | -0.57 |
| Net Debt / EBITDA | -3.38 | -3.38 | -4.76 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -2.55 | -2.95 | -5.95 | — | — | — | — | — | — | — |
| Interest Coverage | — | — | 12873.00 | -5106.47 | -182.97 | -337.79 | -151.44 | -17.61 | -10.72 | -5.59 | -10.39 |
Net cash position: cash ($363M) exceeds total debt ($40M)
VCYT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Veracyte, Inc.'s current ratio of 8.15x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 7.81x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 4.66x to 8.15x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.15 | 8.15 | 4.73 | 4.66 | 3.97 | 3.79 | 22.39 | 10.74 | 7.42 | 4.48 | 6.38 |
| Quick Ratio | 7.81 | 7.81 | 4.46 | 4.40 | 3.74 | 3.61 | 22.11 | 10.35 | 7.16 | 4.04 | 6.08 |
| Cash Ratio | 6.89 | 6.89 | 3.68 | 3.53 | 2.86 | 2.76 | 20.82 | 9.12 | 5.97 | 2.82 | 5.13 |
| Asset Turnover | — | 0.37 | 0.34 | 0.32 | 0.26 | 0.18 | 0.26 | 0.44 | 0.76 | 0.91 | 0.64 |
| Inventory Turnover | 7.65 | 7.65 | 6.79 | 7.00 | 7.11 | 6.63 | 8.90 | 5.37 | 9.72 | 5.30 | 7.33 |
| Days Sales Outstanding | — | 31.52 | 38.10 | 40.82 | 54.18 | 68.94 | 57.36 | 58.61 | 52.24 | 64.51 | 49.10 |
VCYT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Veracyte, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 2.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.0% | 1.9% | 0.8% | — | — | — | — | — | — | — | — |
| FCF Yield | 3.9% | 3.7% | 2.1% | 1.7% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $81M | $78M | $73M | $72M | $68M | $53M | $46M | $37M | $34M | $29M |
Peer Comparison
Compare VCYT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 VCYTYou | $3B | 49.7 | 30.7 | 25.7 | 69.6% | 14.3% | 5.3% | 5.6% | 0.4 |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 NTRA | $31B | -144.6 | — | 285.5 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 CDNA | $1B | -53.6 | — | 30.7 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 ACNB | $549M | 14.7 | 16.1 | 10.4 | 73.7% | 27.3% | 10.2% | 5.3% | 6.2 |
 PAHC | $2B | 36.3 | 15.7 | 41.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 NEOG | $2B | -1.8 | 20.7 | — | 47.1% | 1.1% | -41.9% | 0.2% | 6.8 |
 PACB | $498M | -0.9 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
See VCYT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VCYT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VCYT vs EXAS
Side-by-side business, growth, and profitability comparison vs Exact Sciences Corporation.
Start ComparisonVCYT — Frequently Asked Questions
Quick answers to the most common questions about buying VCYT stock.
What is Veracyte, Inc.'s P/E ratio?
Veracyte, Inc.'s current P/E ratio is 49.7x. The historical average is 89.5x.
What is Veracyte, Inc.'s EV/EBITDA?
Veracyte, Inc.'s current EV/EBITDA is 30.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 52.8x.
What is Veracyte, Inc.'s ROE?
Veracyte, Inc.'s return on equity (ROE) is 5.3%. The historical average is -57.0%.
Is VCYT stock overvalued?
Based on historical data, Veracyte, Inc. is trading at a P/E of 49.7x. Compare with industry peers and growth rates for a complete picture.
What are Veracyte, Inc.'s profit margins?
Veracyte, Inc. has 69.6% gross margin and 14.3% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Veracyte, Inc. have?
Veracyte, Inc.'s Debt/EBITDA ratio is 0.4x, indicating low leverage. A ratio below 2x is generally considered financially healthy.